Trial ID 21320 | Maryland Oncology Hematology Trial ID 21320 – Maryland Oncology Hematology

Trial ID 21320

Trial Information - Phase I/II

A Phase 1/2 Open-Label, Dose-Escalation and Clinical Response Study of Quaratusugene Ozeplasmid in Combination with Osimertinib in Patients with Advanced, EGFR-Mutant, Metastatic Non-Small Cell Lung Cancer who have Progressed after Treatment with Osimertinib

Disease Specifics: (NSCLC/ EGFR mutatnt)

Protocol ID: ONC-003

Sponsor: Genprex, Inc

Status: OPEN TO ENROLLMENT

Contact us regarding Clinical Trials at MOHRSCH@usoncology.com
or call us at 877-664-7724

Disease Types

Lung

Investigator

Wallmark MD, John

Status

OPEN TO ENROLLMENT

Sponsor

Genprex, Inc

Quality Care Close to Home


View our locations on map!

Sign Up Today For Our E-Newsletter

  • This field is for validation purposes and should be left unchanged.
United in Healing with The US Oncology Network - Maryland Oncology Hematology